These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30854978)

  • 21. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
    Vakhapova V; Auriel E; Karni A
    Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm.
    Vitale DC; Piazza C; Sinagra T; Urso V; Cardì F; Drago F; Salomone S
    Clin Drug Investig; 2013 Dec; 33(12):885-91. PubMed ID: 24085590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formulation and evaluation of microemulsion-based hydrogel for topical delivery.
    Sabale V; Vora S
    Int J Pharm Investig; 2012 Jul; 2(3):140-9. PubMed ID: 23373005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.
    Rushton DN; Lloyd AC; Anderson PM
    Pharmacoeconomics; 2002; 20(12):827-37. PubMed ID: 12236804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spasticity: a review.
    Young RR
    Neurology; 1994 Nov; 44(11 Suppl 9):S12-20. PubMed ID: 7970006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tizanidine--initial pharmacokinetic studies in patients with spasticity.
    Heazlewood V; Symoniw P; Maruff P; Eadie MJ
    Eur J Clin Pharmacol; 1983; 25(1):65-7. PubMed ID: 6617726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
    Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
    Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tizanidine for spasticity.
    Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
    [No Abstract]   [Full Text] [Related]  

  • 30. Role of tizanidine in the treatment of spasticity.
    Neurology; 1994 Nov; 44(11 Suppl 9):S1-80. PubMed ID: 7970005
    [No Abstract]   [Full Text] [Related]  

  • 31. Enhanced
    Madhavi N; Battu H
    J Microencapsul; 2024 Mar; 41(2):127-139. PubMed ID: 38410926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
    Medici M; Pebet M; Ciblis D
    Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease.
    Ogawa N; Asanuma M; Hirata H; Ota Z; Yamawaki Y; Yamamoto M
    J Int Med Res; 1992 Feb; 20(1):78-86. PubMed ID: 1568522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gellified Emulsion of Ofloxacin for Transdermal Drug Delivery System.
    Jagdale S; Pawar S
    Adv Pharm Bull; 2017 Jun; 7(2):229-239. PubMed ID: 28761825
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization.
    Khalil RM; Abdelbary A; Kocova El-Arini S; Basha M; El-Hashemy HA
    J Liposome Res; 2019 Jun; 29(2):171-182. PubMed ID: 30221568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microemulsion-loaded hydrogel formulation of butenafine hydrochloride for improved topical delivery.
    Pillai AB; Nair JV; Gupta NK; Gupta S
    Arch Dermatol Res; 2015 Sep; 307(7):625-33. PubMed ID: 26006164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacological treatment of spasticity in multiple sclerosis].
    Heinzlef O; Monteil-Roch I
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S62-8. PubMed ID: 22721367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization.
    Gannu R; Palem CR; Yamsani VV; Yamsani SK; Yamsani MR
    Int J Pharm; 2010 Mar; 388(1-2):231-41. PubMed ID: 20060457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population.
    Smith HS; Barton AE
    Am J Hosp Palliat Care; 2000; 17(1):50-8. PubMed ID: 11094920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation and evaluation of tretinoin microemulsion based on pseudo-ternary phase diagram.
    Moghimipour E; Salimi A; Leis F
    Adv Pharm Bull; 2012; 2(2):141-7. PubMed ID: 24312785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.